CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 12 enrolled
Drug / intervention
Memantinedrug
Likely dose
Memantine 30mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00880685
NCT00880685Phase 2Completed

Memantine Treatment of Kleptomania: An Open-Label Study

University of Chicago·interventional·Posted Apr 14, 2009·Updated May 24, 2021

In Brief

A Phase 2 clinical trial evaluating Memantine for Kleptomania. Completed, enrolled 12 participants across 1 site.

Detailed Summary

The goal of the proposed study is to evaluate the efficacy and safety of memantine in kleptomania.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKleptomania
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 14, 2009
Enrollment StartMar 1, 2009
Primary CompletionMay 1, 2012
Study CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 17.2 years ago

Interventions

Memantinedrug

10-30mg, daily for 8 weeks